{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:02Z","timestamp":1787002982399,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Long noncoding RNAs (lncRNAs) play an essential role in tumor progression. Few researches focused on the clinical and biological relevance of lncRNAs in peripheral T cell lymphoma (PTCL). In this research, a novel lncRNA (ENST00000503502) was identified overexpressed in the main subtypes of PTCL, and designated as T cell lymphoma-associated lncRNA1 (TCLlnc1). Serum TCLlnc1 was associated with extranodal involvement, high-risk International Prognostic Index, and poor prognosis of the patients. Both in vitro and in vivo, overexpression of TCLlnc1 promoted T-lymphoma cell proliferation and migration, both of which were counteracted by the knockdown of TCLlnc1 using small interfering RNAs. As the mechanism of action, TCLlnc1 directly interacted with transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and Y-box binding protein-1 (YBX1) by acting as a modular scaffold. TCLlnc1\/HNRNPD\/YBX1 complex upregulated transcription of\n                    <jats:italic>TGFB2<\/jats:italic>\n                    and\n                    <jats:italic>TGFBR1<\/jats:italic>\n                    genes, activated the tumor growth factor-\u03b2 signaling pathway, resulting in lymphoma progression, and might be a potential target in PTCL.\n                  <\/jats:p>","DOI":"10.1038\/s41419-021-03594-y","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T05:03:51Z","timestamp":1616648631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes"],"prefix":"10.1038","volume":"12","author":[{"given":"Ping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Meng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Janin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-9328","authenticated-orcid":false,"given":"Chao-Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-0169","authenticated-orcid":false,"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-1616","authenticated-orcid":false,"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"3594_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage, J. O. The aggressive peripheral T-cell lymphomas: 2017. Am. J. Hematol. 92, 706\u2013715 (2017).","journal-title":"Am. J. Hematol."},{"key":"3594_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21589","volume":"70","author":"E Marchi","year":"2020","unstructured":"Marchi, E. & O\u2019Connor, O. A. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J. Clin. 70, 47\u201370 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"3594_CR3","doi-asserted-by":"publisher","unstructured":"Casulo, C. et al. T-cell lymphoma: recent advances in characterization and new opportunities for treatment. J. Natl Cancer Inst. 109, https:\/\/doi.org\/10.1093\/jnci\/djw248 (2017).","DOI":"10.1093\/jnci\/djw248"},{"key":"3594_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin, F., Landstrom, J., Jerkeman, M. & Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124, 1570\u20131577 (2014).","journal-title":"Blood"},{"key":"3594_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajh.24992","volume":"93","author":"JY Zhang","year":"2018","unstructured":"Zhang, J. Y. et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am. J. Hematol. 93, 394\u2013400 (2018).","journal-title":"Am. J. Hematol."},{"key":"3594_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","volume":"126","author":"G Hapgood","year":"2015","unstructured":"Hapgood, G. & Savage, K. J. The biology and management of systemic anaplastic large cell lymphoma. Blood 126, 17\u201325 (2015).","journal-title":"Blood"},{"key":"3594_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/ajh.24203","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox, R. A. A three-signal model of T-cell lymphoma pathogenesis. Am. J. Hematol. 91, 113\u2013122 (2016).","journal-title":"Am. J. Hematol."},{"key":"3594_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2019.05.007","volume":"141","author":"J Yang","year":"2019","unstructured":"Yang, J. & Wang, X. Role of long non-coding RNAs in lymphoma: a systematic review and clinical perspectives. Crit. Rev. Oncol.\/Hematol. 141, 13\u201322 (2019).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"3594_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0977-3","volume":"18","author":"Z Zheng","year":"2019","unstructured":"Zheng, Z. et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol. Cancer 18, 54 (2019).","journal-title":"Mol. Cancer"},{"key":"3594_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.3192","volume":"47","author":"MK Iyer","year":"2015","unstructured":"Iyer, M. K. et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 47, 199\u2013208 (2015).","journal-title":"Nat. Genet."},{"key":"3594_CR11","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1038\/onc.2017.184","volume":"36","author":"WX Peng","year":"2017","unstructured":"Peng, W. X., Koirala, P. & Mo, Y. Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 36, 5661\u20135667 (2017).","journal-title":"Oncogene"},{"key":"3594_CR12","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan, A., Soleimani, M. & Mandal, S. S. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 77, 3965\u20133981 (2017).","journal-title":"Cancer Res."},{"key":"3594_CR13","doi-asserted-by":"publisher","first-page":"12348","DOI":"10.1002\/jcb.28500","volume":"120","author":"X Zhao","year":"2019","unstructured":"Zhao, X. & Tian, X. Knockdown of long noncoding RNA HOTAIR inhibits cell growth of human lymphoma cells by upregulation of miR-148b. J. Cell. Biochem. 120, 12348\u201312359 (2019).","journal-title":"J. Cell. Biochem."},{"key":"3594_CR14","doi-asserted-by":"publisher","first-page":"172976","DOI":"10.1016\/j.ejphar.2020.172976","volume":"875","author":"S Ghafouri-Fard","year":"2020","unstructured":"Ghafouri-Fard, S., Esmaeili, M. & Taheri, M. Expression of non-coding RNAs in hematological malignancies. Eur. J. Pharmacol. 875, 172976 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"3594_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0743-3","volume":"16","author":"H YiRen","year":"2017","unstructured":"YiRen, H. et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol. Cancer 16, 174 (2017).","journal-title":"Mol. Cancer"},{"key":"3594_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt, A. M. & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452\u2013463 (2016).","journal-title":"Cancer Cell"},{"key":"3594_CR17","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/cas.13642","volume":"109","author":"A Sanchez Calle","year":"2018","unstructured":"Sanchez Calle, A., Kawamura, Y., Yamamoto, Y., Takeshita, F. & Ochiya, T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 109, 2093\u20132100 (2018).","journal-title":"Cancer Sci."},{"key":"3594_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00739-0","volume":"12","author":"MC Cai","year":"2020","unstructured":"Cai, M. C. et al. CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. Genome Med. 12, 41 (2020).","journal-title":"Genome Med."},{"key":"3594_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.17116\/patol20198103159","volume":"81","author":"IL Polyatskin","year":"2019","unstructured":"Polyatskin, I. L., Artemyeva, A. S. & Krivolapov, Y. A. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors. Arkhiv Patologii 81, 59\u201365 (2019).","journal-title":"Arkhiv Patologii"},{"key":"3594_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong, J. et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell 37, 403\u201319.e6 (2020).","journal-title":"Cancer Cell"},{"key":"3594_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"3594_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"3594_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"3594_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"3594_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3594_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/leu.2013.291","volume":"28","author":"ZX Yan","year":"2014","unstructured":"Yan, Z. X. et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia 28, 880\u2013887 (2014).","journal-title":"Leukemia"},{"key":"3594_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41419-019-1424-5","volume":"10","author":"W Si","year":"2019","unstructured":"Si, W. et al. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity. Cell Death Dis. 10, 206 (2019).","journal-title":"Cell Death Dis."},{"key":"3594_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-8722-6-3","volume":"6","author":"J Zou","year":"2013","unstructured":"Zou, J. et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J. Hematol. Oncol. 6, 3 (2013).","journal-title":"J. Hematol. Oncol."},{"key":"3594_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"3594_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01161-1","volume":"19","author":"D Jin","year":"2020","unstructured":"Jin, D. et al. m(6)A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107\/LATS2-mediated YAP activity in NSCLC. Mol. Cancer 19, 40 (2020).","journal-title":"Mol. Cancer"},{"key":"3594_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41419-020-03071-y","volume":"11","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1\/HK2 modification. Cell Death Dis. 11, 911 (2020).","journal-title":"Cell Death Dis."},{"key":"3594_CR32","volume":"35","author":"P Zhao","year":"2021","unstructured":"Zhao, P. et al. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1\u03b1 in clear cell renal cell carcinoma. FASEB J. 35, e21160 (2021).","journal-title":"FASEB J."},{"key":"3594_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1145-5","volume":"19","author":"M Han","year":"2020","unstructured":"Han, M. et al. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol. Cancer 19, 26 (2020).","journal-title":"Mol. Cancer"},{"key":"3594_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41592-019-0330-1","volume":"16","author":"M Ramanathan","year":"2019","unstructured":"Ramanathan, M., Porter, D. F. & Khavari, P. A. Methods to study RNA-protein interactions. Nat. Methods 16, 225\u2013234 (2019).","journal-title":"Nat. Methods"},{"key":"3594_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41556-019-0311-8","volume":"21","author":"RW Yao","year":"2019","unstructured":"Yao, R. W., Wang, Y. & Chen, L. L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 21, 542\u2013551 (2019).","journal-title":"Nat. Cell Biol."},{"key":"3594_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41571-018-0035-x","volume":"15","author":"S Anfossi","year":"2018","unstructured":"Anfossi, S., Babayan, A., Pantel, K. & Calin, G. A. Clinical utility of circulating non-coding RNAs - an update. Nat. Rev. Clin. Oncol. 15, 541\u2013563 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3594_CR37","doi-asserted-by":"publisher","unstructured":"Seoane, J. & Gomis, R. R. TGF-\u03b2 family signaling in tumor suppression and cancer progression. Cold Spring Harbor Perspect. Biol. 9, https:\/\/doi.org\/10.1101\/cshperspect.a022277 (2017).","DOI":"10.1101\/cshperspect.a022277"},{"key":"3594_CR38","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","volume":"194","author":"TP Chang","year":"2015","unstructured":"Chang, T. P., Poltoratsky, V. & Vancurova, I. Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J. Immunol. 194, 2942\u20132953 (2015).","journal-title":"J. Immunol."},{"key":"3594_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard, R. B. et al. Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J. Immunother. Cancer 6, 47 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"3594_CR40","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","volume":"25","author":"V Santini","year":"2019","unstructured":"Santini, V. et al. Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. Clin. Cancer Res. 25, 6976\u20136985 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3594_CR41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","volume":"135","author":"T Geuens","year":"2016","unstructured":"Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851\u2013867 (2016).","journal-title":"Hum. Genet."},{"key":"3594_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.tig.2017.11.005","volume":"34","author":"Q Sun","year":"2018","unstructured":"Sun, Q., Hao, Q. & Prasanth, K. V. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 34, 142\u2013157 (2018).","journal-title":"Trends Genet."},{"key":"3594_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-019-1150-y","volume":"38","author":"J Li","year":"2019","unstructured":"Li, J., He, M., Xu, W. & Huang, S. LINC01354 interacting with hnRNP-D contributes to the proliferation and metastasis in colorectal cancer through activating Wnt\/\u03b2-catenin signaling pathway. J. Exp. Clin. Cancer Res. 38, 161 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"3594_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/bies.10300","volume":"25","author":"K Kohno","year":"2003","unstructured":"Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M. & Kuwano, M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25, 691\u2013698 (2003).","journal-title":"BioEssays"},{"key":"3594_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03265-1","volume":"9","author":"MM Ali","year":"2018","unstructured":"Ali, M. M. et al. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat. Commun. 9, 883 (2018).","journal-title":"Nat. Commun."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03594-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:40:12Z","timestamp":1669902012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03594-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03594-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have agreed to publish this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Shanghai Ruijin Hospital review board with informed consent obtained in accordance with the Declaration of Helsinki. Animals were used according to the protocols approved by Shanghai Ruijin Hospital Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"321"}}